NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology products to improve the lives of patients with cancer.
Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our mission is to change the cancer treatment paradigm and make a difference in patient lives every day.
Nicholas N. Vahanian, MD
Eugene P. Kennedy, MD
Chief Medical Officer
Chief Financial Officer
Mario Mautino, PhD
Senior Vice President, Research and Development, Intellectual Property Officer
Gabriela R. Rossi, PhD
Vice President, Biologics Development